🔎 Trials Near Me

Home › Marginal Zone Lymphoma › Tennessee

Pag-aaral pangklinika para sa Marginal Zone Lymphoma sa Tennessee

7 pag-aaral para sa Marginal Zone Lymphoma ang naghahanap ng mga kalahok sa mga site sa Tennessee.

Mga Lungsod sa Tennessee

Opisyal na teksto ng pag-aaral (English)

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • Tennesse Oncology Chattanooga Downtown, Chattanooga
  • Tennessee Oncology, Pllc Nashville, Nashville
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05006716

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • SCRI Oncology Partners, Nashville
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07101328

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

  • Vanderbilt University, Nashvile
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT05296070

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • TriStar BMT, Nashville
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

  • Tennessee Oncology, Nashville
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 24, 2026 · NCT07121946

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  • Tennessee Oncology, Nashville
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 20, 2026 · NCT04830137

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Memphis
  • Massive Bio SYNERGY-AI site, Nashville
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.